Korro Bio, Inc. (KRRO) Dividend History

Korro Bio, Inc. (KRRO) is a biotechnology company focused on developing targeted gene editing and gene regulation therapies. The company specializes in leveraging innovative nucleic acid-based approaches to treat rare and serious diseases by directly modifying or regulating affected genes.

One Kendall Square. Building 600-700, Cambridge, MA, 02139
Phone: 617-468-1999
Website: https://www.korrobio.com

Dividend History

Korro Bio, Inc. currently does not pay dividends

Company News

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

Korro Bio, a clinical-stage biopharmaceutical company, announced that the FDA has granted orphan drug designation to its investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110 is currently being evaluated in a Phase 1/2a clinical study, and the company expects to report interim data in the second half of 2025.

GlobeNewswire Inc.
4 Biotech Stocks With AI, Machine Learning Prowess

The article discusses four biotech companies leveraging AI and machine learning technology to improve drug discovery and development processes. These companies are Absci, Firefly Neuroscience, Korro Bio, and NeuroSense Therapeutics.

Investing.com

Featured Companies: ABSI AIFF NRSN
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks

Novo Nordisk and Korro Bio announced a $530 million drug development collaboration, but this is not seen as a threat to Moderna as the companies are working on different approaches to mRNA technology.

The Motley Fool

Featured Companies: MRNA
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained editing activity for KRRO-110, its development candidate for the treatment of AATD.

GlobeNewswire Inc.
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024

GlobeNewswire Inc.

Dividend data last updated 06/08/2025 00:10:32 UTC